Prostatype Genomics AB (PROGEN) Stock Overview

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. Prostatype Genomics AB (publ) was incorporated in 2007 and is based in Solna, Sweden.